Please try another search
For the three months ended 31 March 2015, Synageva Biopharma Corp revenues decreased 42% to $927K. Net loss increased 64% to $59.6M. Revenues reflect Royalty Revenues decrease of 36% to $927K, Collaboration and license revenue decrease from $139K to $0K. Higher net loss reflects Research & development expenses increase of 33% to $27.6M (expense), General and administrative expenses increase from $4.3M to $9.6M (expense).
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Revenue | 0.93 | 1.24 | 1.33 | 2.34 |
Gross Profit | ||||
Operating Income | -59.17 | -57.31 | -48.04 | -50.31 |
Net Income | -59.6 | -57.66 | -48.32 | -50.24 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Total Assets | 768.55 | 504.2 | 548.21 | 593.24 |
Total Liabilities | 33.42 | 30.96 | 28.57 | 32.62 |
Total Equity | 735.13 | 473.24 | 519.64 | 560.61 |
Period Ending: | Mar 31, 2015 | Dec 31, 2014 | Sep 30, 2014 | Jun 30, 2014 |
---|---|---|---|---|
Period Length: | 3 Months | 12 Months | 9 Months | 6 Months |
Cash From Operating Activities | -47.44 | -150.12 | -109.72 | -69.59 |
Cash From Investing Activities | -251.02 | -44.62 | -86.24 | -131.72 |
Cash From Financing Activities | 314.4 | 215.36 | 210.43 | 209.64 |
Net Change in Cash | 15.92 | 20.52 | 14.4 | 8.32 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review